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ABSTRACT 
Introduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a 
small- and medium-sized vasculitis classically seen in adult patients with peak onset 
near the fifth to seventh decade of life. There is little data on ANCA-associated 
vasculitis in pediatric patients and most studies have limited follow-up.  
Methods: This is a retrospective chart review of 22 patients in a single institution from 
1991 to 2013.  
Results: Of the 22 patients in our institution with ANCA-positive glomerulonephritis, 
eight patients (36 %) required renal replacement therapy (RRT) at diagnosis; four of 
these patients recovered sufficient renal function to initially discontinue dialysis. Five 
patients (23 %) were treated with plasmapheresis at presentation. The median time 
from presentation until first clinical or serologic relapse was 1.7 ± 1.2 years. After a 
median follow-up of 5.8 years, just over half of our patients have chronic kidney disease 
(CKD) stages 1-3 (55 %). Seven (32 %) patients progressed to end-stage renal disease 
(ESRD) and eventually required kidney transplant. 
Conclusion: ANCA-associated glomerulonephritis is a rare disorder in children. 
Presentation and outcomes vary significantly amongst patients. More research is 
required to follow these patients who are diagnosed in childhood to further characterize 
the long term outcome of the disease. 
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ABBREVIATIONS: 
AAV: ANCA-associated vasculitis 
ANCA: Anti-neutrophil cytoplasmic antibody 
AGN: ANCA-associated glomerulonephritis classification 
c-ANCA: cytoplasmic anti-neutrophil cytoplasmic antibody 
CKD: Chronic kidney disease 
ESRD: End stage renal disease 
EPA: Eosinophilic granulomatosis with polyangiitis 
GFR: Glomerular filtration rate 
GPA: Granulomatosis with polyangiitis 
MPA: Microscopic polyangiitis 
MPO: Myeloperoxidase 
PR3: Proteinase 3 
p-ANCA: perinuclear anti-neutrophil cytoplasmic antibody 
RPGN: Rapidly progressing glomerulonephritis 
RRT: Renal replacement therapy 
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INTRODUCTION 
Dr. J. Charles Jennette and Dr. Ronald J. Falk first characterized the association 
of anti-neutrophil cytoplasmic antibodies (ANCA) with necrotizing vasculitis in the 1980s 
and 1990s [1]. ANCA-associated vasculitis (AAV) is a small- and medium-sized 
vasculitis which has since been classified in to three separate entities: granulomatosis 
with polyangiitis (GPA, formerly Wegener’s granulomatosis), microscopic polyangiitis 
(MPA) and eosinophilic granulomatosis with polyangiits (EGPA) [2]. It is a disease 
classically seen in adults and is rare in the pediatric population. The peak age of onset 
is commonly between the fifth and seventh decade of life [3]. As a result, much of the 
data and treatment protocols are extrapolated from adult data and applied to pediatric 
patients. 
The data on ANCA-associated renal disease in children is mostly in the form of 
case series and retrospective studies with limited follow-up. Similar to other childhood 
chronic diseases, children with AAV differ from adults in that they have a longer 
anticipated life span over which their disease must be managed. The peak age of onset 
of AAV in the pediatric population is during late childhood and adolescence, a critical 
time for growth as well as emotional, physical and reproductive development [4-6]. 
Critical therapeutic decisions must be made to maximize quality of life as well as long-
term renal and overall survival. Thus, longitudinal data in this patient population is 
needed to see the potential evolution of disease through childhood, adolescence and 
into adulthood. 
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The purpose of this study is to describe pediatric ANCA-associated 
glomerulonephritis at a single center and to compare our experience with previously 
published adult and pediatric literature. 
 
METHODS 
 This study was approved by the Institutional Review Board (IRB) governing 
Indiana University School of Medicine. It is a retrospective chart review of 22 patients 
with ANCA-positive glomerulonephritis diagnosed or managed from 1991 to 2013 within 
the Pediatric Nephrology and Hypertension Division at Riley Hospital for Children at 
Indiana University Health, a tertiary care center with a pediatric nephrology division in 
addition to other pediatric subspecialties. The IRB granted a waiver of consent for this 
study. We identified patients from the GE-Centricity Business (IDX) billing system based 
on ICD-9 codes available to our institution for billing. The following codes generated a 
list of 213 patients: 446.0 polyarteritis nodosa and allied conditions, 580.4 acute 
glomerulonephritis, 582.0 chronic glomerulonephritis, 584.5 acute kidney failure with 
tubular necrosis, and 584.9 acute kidney failure. From this list, 23 patients were 
identified as ANCA-positive. One patient was ANCA-positive but upon further review 
had questionable renal involvement and was excluded. In total, 22 patients with ANCA-
positive disease and active renal involvement were included in the study.  
Patients were selected if they met the following criteria: (1) ANCA-positive 
serology with clinical renal involvement and/or (2) biopsy findings consistent with the 
diagnosis of ANCA-positive glomerulonephritis. Charts were reviewed for demographic 
information as well as clinical and laboratory characteristics at presentation, relapse and 
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most recent follow-up. The patients were considered to have suffered a serologic 
relapse if their ANCA titer started to rise after a previous period of stability or became 
positive after having been negative. Patients were considered to have had a clinical 
relapse if they developed symptoms that required changes in medical therapy. The 
estimated glomerular filtration rate for each patient was calculated using the modified 
Schwartz equation [7]. Length of follow-up was determined from the time of presentation 
to the time of transplant or to the time of most recent follow-up for those patients who 
did not progress to end-stage renal disease (ESRD) or to the date of most recent 
available clinical information. All patients who progressed to ESRD were transplanted. 
 
Statistics 
 Statistical analysis was performed using IBM SPSS 23® statistical software. 
Continuous variables were compared using the Mann-Whitney-U test. 
 
RESULTS 
Demographic information 
 A total of 1017 unique patients were diagnosed with glomerulonephritis from 
1991 to 2013 at our institution; 22 patients were identified as having ANCA-positive 
glomerulonephritis, making the proportion of patients with ANCA-associated 
glomerulonephritis 2.16 %. Of the 22 patients in our institution with ANCA-positive 
glomerulonephritis, 13 patients (59 %) were female. The median age at presentation 
was 13.7 years (IQR 11.6—15.7). Males presented at an older age than females, but 
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this was not statistically significant (p=0.08). See Table 1 for a summary of patient 
demographics and presenting characteristics. 
 
Clinical presentation and initial treatment 
 Twenty of 22 patients had documented systemic symptoms reported at 
presentation. Diagnosis and initial management took place at outside institutions for two 
patients. Figure 1 characterizes the percentage of patients with the most common 
presenting symptoms. The most commonly reported symptoms were respiratory in 
nature, with 55 % of patients having documented pulmonary or sinus involvement. 
Other patients presented with non-specific complaints of body aches, malaise and 
fatigue. One patient presented with heart failure requiring ionotropic support. 
 The renal involvement at presentation varied considerably, details of which are 
shown in Table 1. All of our patients presented with hematuria, proteinuria or both. 
Renal biopsy was performed on 21 patients, 19 of which were performed at our 
institution. One patient did not have a biopsy performed due to the critical nature of the 
patient’s condition at presentation. We classified the renal biopsies into the most 
appropriate histopathologic categories: focal, crescentic, mixed, and sclerotic according 
to the ANCA-associated glomerulonephritis (AGN) classification [8-10].  
Of the twenty patients initially diagnosed and managed at our hospital, all were 
treated with varying regimens at presentation. Every patient received a 
methylprednisolone pulse (500 mg to 2000 mg per dose), varying between 2 and 6 
doses over 2 to 12 days. Following administration of pulse-dose steroids, each of the 
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patients was transitioned to oral prednisone at 2 mg/kg/day up to a maximum dose of 
60 mg/day. With the exception of four patients, all patients were treated with either oral 
or IV cyclophosphamide. Maintenance immunosuppression for each individual patient 
was left to the discretion of the treating physician and therefore no standard protocol 
was used. However, maintenance therapy often consisted of a combination of 
prednisone with another agent including mycophenalate mofetil, azathioprine, or 
hydroxychloroquine. One patient was treated with twice weekly etanercept injections.  
Eight patients (36 %) required renal replacement therapy (RRT) at the time of 
initial presentation; four of these patients recovered sufficient renal function to 
discontinue dialysis. Five patients (23 %) were treated with plasmapheresis at 
presentation. The decision to perform plasmapheresis was at the discretion of the 
attending nephrologist and generally was reserved for those with the most severe 
disease at presentation or those who had a slow response to initial therapy. One patient 
who required plasmapheresis did not require concurrent RRT; three years following 
diagnosis, this patient remains off RRT with CKD stage 3. Of the remaining four patients 
who required RRT and were treated with plasmapheresis, two patients recovered renal 
function. One was able to discontinue continuous veno-venous hemofiltration after 25 
days. The other patient’s dialysis duration was unavailable. They were both able to 
remain off dialysis at most recent follow-up with CKD Stage 2 at 3 and 6 years following 
diagnosis.  
 
Failure of induction therapy and relapse 
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Following induction therapy, two of our patients (9 %) did not successfully enter 
remission. One patient was treated with methylprednisolone pulses as well as weekly 
methotrexate, intravenous cyclophosphamide in addition to hydroxychloroquine but 
ultimately died in the acute phase of the illness. In the days leading to up to death, the 
cyclophosphamide and methotrexate were discontinued due to persistent neutropenia. 
The patient eventually succumbed to complications of pulmonary fibrosis. The other 
patient who failed induction therapy was treated with methylprednisolone, intravenous 
cyclophosphamide, azathioprine, mycophenolate mofetil and required dialysis and 
eventually kidney transplantation. 
Twelve patients (55 %) experienced at least one serologic or clinical relapse. Of 
these patients, 9 suffered from solely serologic relapses, 2 experienced serologic 
relapses associated with clinical symptoms, and 1 patient had a documented clinical 
relapse without evidence of serologic relapse. The median length of time from 
presentation until first clinical or serologic relapse was 1.7 years (IQR 1.0—2.2). Figure 
2 is a Kaplan-Meier curve illustrating the relapse-free survival for all 22 patients. At least 
8 patients (67 %) suffered their first relapse while on immunosuppressive medication. Of 
these 8 patients, 3 patients relapsed while on mycophenolate mofetil in combination 
with prednisone, 1 on azathioprine in combination with every-other-day prednisone (40 
mg), 1 on cyclophosphamide in combination with daily prednisone (5 mg), and 3 
relapsed while on every-other-day prednisone (50 mg, 30 mg, 5 mg). Seven patients 
(32 %) experienced more than one relapse.  
All 3 patients with a confirmed clinical component to his or her first relapse were 
treated with increases in immunosuppression, including increases in prednisone and 
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mycophenolate mofetil, and in the case of 1 patient, with the initiation of high-dose 
methylprednisolone and cyclophosphamide. Despite aggressive treatment, two of these 
patients progressed to ESRD.  
 Not all serologic relapses were treated with increases in immunosuppressive 
therapy. Four patients with first-time serologic relapses were documented to have had 
increases in immunosuppression prescribed by their provider. There was no 
standardized treatment protocol for treatment of clinical or serologic relapse, so it is 
difficult to draw conclusions regarding treatment efficacy based on our data.  
 
ESRD and transplant 
The median length of time to follow-up for all patients was 5.8 years (IQR 3.0-
8.3). Two patients were lost to follow-up. Seven (32 %) patients progressed to ESRD 
and required kidney transplant. Median estimated glomerular filtration rate at most 
recent follow-up of those patients who did not progress to ESRD was 61.1 
mL/min/1.73m2 (IQR 49.3—78.0). The median time from presentation to kidney 
transplant was 3.5 years (IQR 2.0—8.3). 
Table 2 illustrates the renal outcomes for our patients. Of the eight patients that 
required dialysis at presentation, five patients (63 %) progressed to require kidney 
transplantation. The median creatinine at presentation for those patients who did 
eventually progress to ESRD was 8.85 mg/dL (IQR 2.4—28.9). The creatinine of those 
patients who did not progress to ESRD overall trended lower at presentation with a 
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median of 2.2 mg/dL (IQR 0.9—5.6). However, this difference was not statistically 
significant.  
Two patients who progressed to ESRD did not present with a need for dialysis. 
For those 2 patients, the serum creatinine at presentation was 1.5 mg/dL and 2.7 mg/dL 
at ages 17.4 years and 11.1 years, respectively; one patient was PR3-positive at 
presentation while the other patient was actually ANCA negative at presentation and 
later seroconverted to MPO-positive disease. One of these patients actually failed 
induction therapy, and the other patient had frequently-relapsing disease with 
subsequent decline in renal function. No patients in our study have had the rare, but 
reported, complication of recurrence of disease in the transplanted kidney.  
 
DISCUSSION 
This is one of the largest studies to describe ANCA-positive glomerular disease 
in children with one of the longest follow-up durations to date. To our knowledge, there 
are only a handful of recent retrospective studies that describe clinical characteristics of 
children with this disease; data are sparse in terms of long-term follow-up and 
progression to ESRD. Table 3 is a summary of previously published data on pediatric 
AAV with or without renal involvement. In addition, we determined that ANCA-positive 
glomerulonephritis accounted for 2.16 % of cases of glomerulonephritis at our center, 
documenting that ANCA-positive glomerulonephritis is rare in pediatric patients. 
Our patient demographics are consistent with what has been previously reported 
in the pediatric literature, with peak age of onset during adolescence and a female-
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predominant patient population [5, 11-14]. In the adult literature, it is reported that renal 
involvement in AAV can be so severe as to require dialysis-dependence in 23-60 % of 
these patients [15, 16]. Our study found that 36 % of patients required dialysis at 
diagnosis, which is within the range previously reported in the pediatric literature as well 
[5, 6, 10-13, 17-21]. However, it is important to note that our study is based solely on 
those patients with renal involvement and does not include patients without renal 
involvement. This can be misleading when comparing our study to others, as 100 % of 
our patients suffered from renal involvement and therefore represent the population who 
is at the highest risk for dialysis. 
Even with effective therapies, AAV is a chronic illness. In adults, AAV has been 
reported to have a 90 % two-year mortality if left untreated. Modern treatment protocols 
with high dose steroids, cyclophosphamide, rituximab and plasmapheresis have 
improved the prognosis of this disease, but all are also associated with significant 
morbidities. Also in adult populations, it is documented that induction therapy fails to 
induce remission in approximately 10 % of patients [3]. Moreover, after induction 
therapy and remission, many patients suffer from clinical or serologic relapse, and 
kidney function has been reported to be inversely associated with relapse rate [22].  
Our study’s pediatric data is strikingly similar to the adult data with respect to 
induction therapy and relapsing disease. Ten percent of patients in our study failed to 
respond to initial therapy and over half (55 %) of patients suffered from clinical or 
serologic relapse. Our data also suggest that patients who fail to enter remission with 
induction therapy and those who have more frequent relapses have a worse renal 
outcome. However, our study is biased by the assumption that the time of renal 
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involvement was simultaneous with the time of disease onset. This is not always the 
case for all patients with AAV, as pediatric patients are especially vulnerable to a delay 
in diagnosis, given the rarity of the disease and variability in presenting signs and 
symptoms [14, 23]. In addition, the relapse rate in our study is rather high (55 %). This 
may be a function of the follow-up time of the study, with ANCA titers known to fluctuate 
in individual patients without evidence of clinical disease. Current guidelines do not 
consider solely a change in ANCA titer a relapse, but rather a time for close clinical and 
laboratory monitoring in an individual patient. 
With regards to overall prognosis, the adult literature reports that older age, 
female gender, higher serum creatinine and chronic histologic lesions are predictors for 
worse renal outcome and overall survival [16]. Fourteen to 18 percent of adult patients 
with AAV require permanent dialysis and the disease has a 23-40 % mortality rate by 1 
and 5 years from diagnosis [16, 24]. In our pediatric cohort, the data also suggests that 
a higher creatinine at presentation is a negative prognostic factor in terms of renal 
prognosis, although our results were not statistically significant likely due to the sample 
size. However, the overall renal prognosis and survival is arguably better than that of 
the adult population despite the fact that seven of our patients (32 %) progressed to 
ESRD and required a kidney transplant. Just over half of our patients have CKD stages 
1-3 (55 %) with the median estimated glomerular filtration rate of 61.1 ml/min/1.73m2 for 
those patients who did not progress to ESRD at a median of 5.8 years following 
diagnosis. The mortality rate in our study was much lower (1 patient, 5 %) than what 
has been reported in the adult literature. Additionally, nearly two-thirds of our sample 
had relatively indolent courses and had no need for RRT.  
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This study is a retrospective chart review. As for all studies with this design, there 
are significant biases and limitations. These limitations should not be undermined. For 
example, documented rises in ANCA titers may have been associated with more clinical 
symptoms which were not clearly documented in the paper or electronic medical record, 
limiting our ability to truly document a clinical versus a serologic relapse in these 
patients. In addition, two patients were diagnosed at outside institutions and therefore 
the information surrounding their presentation is limited. Additionally, a statistic 
illustrating the duration from presentation to ESRD in the patients who developed ESRD 
would have been helpful. However, the data collection was limited by what was 
available in the chart and the timing of dialysis initiation was not available for most 
patients.  
The sample size of our study is a relative limitation. This disease is uncommon 
and although we are a fairly high-volume center, approximately 1 patient with this 
disease presents per year at our institution. Nonetheless, our study has a relatively 
large cohort with a relatively long follow-up duration when compared to other published 
pediatric literature on the topic. As such, pediatric patients, in contrast to adults, have 
potentially multiple decades to live with this disease; understanding this disease over 
long periods of time is essential for improvement in the care of these patients.  
 
CONCLUSION 
 ANCA-positive glomerulonephritis is a rare disorder in children. At presentation, 
the degree of renal involvement is quite variable, ranging from mild to very severe renal 
injury. However, nearly two-thirds of our cohort were without need for RRT at a median 
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follow-up time of 5.8 years, indicating that with modern therapies this disease can be 
indolent despite the risk of relapse. Nonetheless, more prospective research is required 
to understand the disease progression in children. 
 
Conflict of interest: The authors have no conflicts of interest to disclose. 
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Gender [n(%)] 
 Male   9 (41) 
 Female  13 (59) 
 
Age (Median in years) 13.7 (IQR 4.2)  
 Male   15.6 (IQR 3.6) 
 Female  11.9 (IQR 4.8) 
 
Serology [n(%)] 
 c-ANCA/PR3  9 (41) 
 p-ANCA/MPO 9 (41) 
 c-ANCA  0 (0) 
 p-ANCA  1 (4.5) 
 PR3   0 (0) 
 MPO   1 (4.5) 
 Both   1 (4.5)  
 Other   1 (4.5) (Initially negative, then seroconverted to p-ANCA) 
 
Median BUN 
(mg/dL)   40.5 (IQR 52)1 
 
Median Creatinine  
(mg/dL)   2.7 (IQR 5.4)2 
 
% with Hematuria  100% 
 
% with Proteinuria  100% 
 
Median Protein:Creatinine  
(mg/mg)   1.5 (IQR 4.1)3 
 
Pathologic Findings on Biopsy [n(%)]4 
 Focal  0 (0) 
 Crescentic 10 (53) 
 Mixed  4 (21) 
 Sclerotic 5 (26) 
 
 
 
 Table 1: Summary of Patient Characteristics at Presentation 
 
                                                 
1 20 of 22 patients have BUN reported at presentation 
2 21 of 22 patients have creatinine reported at presentation 
3 14 of 22 patients have Pr/Cr ratios reported at presentation 
4 2 biopsies at outside institutions not included in classification  
Table 1
Residual Renal function Number of patients 
CKD 1 (eGFR > 90 mL/min/1.73m2) 6 
CKD 2 (eGFR 60-89 mL/min/1.73m2) 3 
CKD 3 (eGFR 30-59 mL/min/1.73m2) 3 
CKD 5/ESRD/Tx (eGFR <15 
mL/min/1.73m2 or dialysis) 
7 
Lost to follow-up 2 
Deceased 1 
TOTAL 22 
   
 
Table 2: Renal Outcomes at Median Follow-up of 5.8 years 
Table 2
 
 
Ellis 
1995 [23] 
Valentini 
1998 [21] 
Bakkaloglu 
2001 [25] 
Hattori 
2001 
[5] 
Belostotsky 
2002 [11] 
Peco-
Antic 
2006 [6] 
Yu 
2006 [14] 
 
 
Akikusa 
2007 [18] 
 
 
Cabral 
2009 [26] 
Arulkumaran 
2011 [12] 
Siomou 
2012 [13] 
Krmar 
2013 [17] 
Noone 
2014 [10] 
Bohm 
2014 [4] 
Basu 
2015 [19] 
 
Khalighi 
2015 [27] 
 
Sacri 
2015 [20] 
 (US)   (Japan)      (UK) (UK)       
n=  5 7 10 31 17 7 20 25 65 8 13 6 40 56 11 21 66 
Length  
of Follow-Up 
(years)5 
 --- 2 ± 1 66 
3.75± 
2.4 
--- 2.95 ± 1.9 1.0 ± 0.43 2.732 --- 19 3.2 ± 2.9 4.4 2.42 --- 1.742 2.56 5.26 
Age at 
 Presentation  
(years)1 
 11.5 ± 2.5 13.0  ± 0.9 126 
11.9 ± 
2.9 
6 12.0 ± 2.6 10.8± 2.8 14.52 14.22 11.5 13.2 ± 2.9 10.6 122 11.72 7.62 142 11.56 
Gender 
F 
(%) 
4 (82) 5 (71) 6 (60) 27 (87) 13 (76) 6 (86) 18 (90) 20 (80) 41 (63.1) 6 (75) 10 (77) 5 (83) 28 (70) 38 (68) 6 (55) 15 (71) 55 (83) 
M  
(%) 
1 (18) 2 (29) 4 (4) 4 (13) 4 (24) 1 (14) 2 (10) 5 (20) 24 (36.9) 2 (25) 11 (23) 1 (17) 12 (30) 18 (32) 5 (45) 6 (29) 11 (17) 
Serology 
MPO 
(%) 
--- --- 10 (100) 
28 
(90.3) 
--- 7 (100) 19 (95) 4 (16) 8 (12.3) 2 (25) 5 (38) 6 (100) 10 (25) 13 (26)  11 (100) 10 (48) 39 (59) 
PR3 
 (%) 
--- --- 0 3 (9.7) --- 0 1 (5) 15 (60) 44 (67.7) 4 (50) 7 (54) 0 (0) 18 (45) 34 (67) 0 7 (33) 22 (33) 
Other 
2 (40)c- 
2 (40)p- 
1 unk 
4 (57) c- 
3 (43) p- 
--- --- 
10 (59) c- 
0 p- 
--- --- 
Unstated 
2 (8), 
ANCA negative 
1 (4) 
43 (66.2) c- 
14 (21.5) p- 
4 ANCA 
negative 
1 PR3 & MPO 
positive 
Neither 
2 (25) 
Neither 
1 (8) 
--- 
19 (47.5) p- 
11 (27.5) c- 
 ANCA negative 
9 (22.5) 
46 (82.7) 
ANCA 
positive 
10 (91) p- 
3 neg; 
1 unk. 
43 (65) c- 
22 (33) p- 
1 (2) both 
Patients with 
Renal 
Involvement 
(%) 
 5 (100) 7 (100) 6 (60) 
31 
(100) 
9 (53) 7 (100) 20 (100) 22 (88) 49 (75.4) 5 (63) 13 (100) 6 (100) 40 (100) 23 (82) 11 (100) 21 (100) 58 (88) 
Dialysis at  
Presentation 
(%) 
 --- 2 (29) --- 7 (23) 1 (6)  2 (29) 5 (25) 5 (20) --- 1 (12.5) 1 (8) 1 (17) 12 (30) --- 9 (82) --- 9 (14) 
Development 
 of ESRD 
(%) 
 --- 1 (14) 4 (40) 9 (29) 1 (6) 2 (29) 10 (50) 3 (12) --- 1 (12.5) 3 (23) 0 14 (35) --- 0 7 (37) 22 (34) 
Table 3:  Summary of Literature Reported on Pediatric ANCA-Associated Vasculitis
                                                          
1 Reported as mean unless otherwise noted 
2 Reported as median 
--- = not available 
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    Ellis 1995 [23] 
Valentini 
1998 [21] 
Bakkaloglu 
2001 [25] 
Hattori 
2001 
[5] 
Belostotsky 
2002 [11] 
Peco‐
Antic 
2006 [6] 
Yu 
2006 [14] 
 
 
Akikusa 
2007 [18] 
 
 
Cabral 
2009 [26] 
Arulkumaran 
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Siomou 
2012 [13] 
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2013 [17] 
Noone 
2014 [10] 
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2014 [4] 
Basu 
2015 [19] 
 
Khalighi 
2015 [27] 
 
Sacri 
2015 [20] 
  (US)      (Japan)            (UK)  (UK)             
n=    5  7  10  31  17  7  20  25  65  8  13  6  40  56  11  21  66 
Length  
of Follow‐Up 
(years)5 
  ‐‐‐  2 ± 1  66  3.75± 2.4  ‐‐‐  2.95 ± 1.9  1.0 ± 0.43  2.732  ‐‐‐  19  3.2 ± 2.9  4.4  2.42  ‐‐‐  1.742  2.56  5.26 
Age at 
 Presentation  
(years)1 
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4 (82)  5 (71)  6 (60)  27 (87)  13 (76)  6 (86)  18 (90)  20 (80)  41 (63.1)  6 (75)  10 (77)  5 (83)  28 (70)  38 (68)  6 (55)  15 (71)  55 (83) 
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(%) 
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Serology 
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PR3 
 (%) 
‐‐‐  ‐‐‐  0  3 (9.7)  ‐‐‐  0  1 (5)  15 (60)  44 (67.7)  4 (50)  7 (54)  0 (0)  18 (45)  34 (67)  0  7 (33)  22 (33) 
Other 
2 (40)c‐ 
2 (40)p‐ 
1 unk 
4 (57) c‐ 
3 (43) p‐  ‐‐‐  ‐‐‐ 
10 (59) c‐ 
0 p‐  ‐‐‐  ‐‐‐ 
Unstated 
2 (8), 
ANCA negative 
1 (4) 
43 (66.2) c‐ 
14 (21.5) p‐ 
4 ANCA 
negative 
1 PR3 & MPO 
positive 
Neither 
2 (25) 
Neither 
1 (8)  ‐‐‐ 
19 (47.5) p‐ 
11 (27.5) c‐ 
 ANCA negative 
9 (22.5) 
46 (82.7) 
ANCA 
positive 
10 (91) p‐  3 neg; 1 unk. 
43 (65) c‐ 
22 (33) p‐ 
1 (2) both 
Patients with 
Renal 
Involvement 
(%) 
  5 (100)  7 (100)  6 (60)  31 (100)  9 (53)  7 (100)  20 (100)  22 (88)  49 (75.4)  5 (63)  13 (100)  6 (100)  40 (100)  23 (82)  11 (100)  21 (100)  58 (88) 
Dialysis at  
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(%) 
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Development 
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(%) 
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1 Reported as mean unless otherwise noted 
2 Reported as median 
--- = not available 
 
